Copyright
©The Author(s) 2024.
World J Orthop. Oct 18, 2024; 15(10): 918-931
Published online Oct 18, 2024. doi: 10.5312/wjo.v15.i10.918
Published online Oct 18, 2024. doi: 10.5312/wjo.v15.i10.918
Table 1 Surface markers of urine-derived stem cells
| Surface markers in USCs | Ref. | |
| MSC-like markers | CD73, CD90, CD29, CD44, CD146 | |
| CD73, CD29, CD44 | ||
| CD73, CD90, CD44, CD146 | ||
| CD73, CD90, CD105 (high), CD44, CD146 | ||
| CD73, CD90, CD146 | ||
| CD73, CD90, CD105, CD29, CD24, CD146 | ||
| CD73, CD90, CD29 | ||
| CD73, CD90, CD29, CD44, CD54, CD166, CD146 | ||
| CD73, CD90, CD105, CD29, CD44 | ||
| CD90, CD29, CD44 | ||
| CD73, CD90, CD105, CD29, CD44, CD166, STRO-1, CD54, CD146 | ||
| CD73, CD90, CD105, CD44 | ||
| CD73, CD90, CD105, STRO-1 (low), CD146 | ||
| CD73, CD90, CD105, CD24, CD29, CD44, CD117, STRO-1, CD146 | ||
| CD29, CD44, CD73, CD90, CD105 (low) | ||
| CD24, CD29, CD34, CD44, CD73, CD90 | ||
| Other pluripotency markers | TRA-1-60, TRA-1-81, SSEA-4, SOX2, OCT4, MYC, KLF4 | |
| SSEA-4 | ||
| OCT4, MYC | ||
| OCT4, NANOG | [20] | |
| CD133 | ||
| Urinary system markers | Nephrin, WT1 | [20] |
| PAX2, PAX8 | ||
| Uroplakin Ia, cytokeratin 7, cytokeratin 19 | ||
| MP markers | PAX7, MYF5, MOYD, desmin, dystrophin, myogenin, α-smooth muscle actin | [24] |
Table 2 Reprogramming methods of urine-derived stem cells
| Reprogramming method | Vectors | Factors | Ref. |
| SeV | SeV | OSKM | [15,43,44,48,49,58,60,63,71] |
| OCT4, SOX2, NANOG, LIN28 | |||
| JDP2, JHDM1B, MKK6, GLIS1, NANOG, ESSRB, SALL4 | |||
| Exogenous plasmids | Epi | KLD4, MYC, OCT4, SOX2, LIN28, shP53 | |
| OCT4, SOX2, KLF4, miR-302-367 | |||
| OCT4, SOX2, NANOG, LIN28, KLF4 and MYC | [85,86] | ||
| OCT4, SOX2, SV40 LT, KLF4 and miR302-367 | |||
| OCT4, SOX2, NANOG, MYC, KLF4, LIN28 | |||
| OCT4, SOX2, KLF4, and miR-302-367 | |||
| pCXLE-hOCT4-shP53-F, pCXLE-hSK, pCXLE-h UL | OSKM, shP53, LIN28 | ||
| TET-ON-induced expression vector | OSKM | ||
| pEP4EO2SET2K | OCT4, SOX2, SV40 LT and KLF4, miR-302b, c, a, d and miR-367 | ||
| SM | Cyclic pifithrin-a, A-83-01, CHIR99021, thiazovivin, NaB, PD0325901 | ||
| mRNA | OSKM LNg | ||
| srRNA | OSKM, NSP 1-4 | ||
| Lentivirus | Lentiviral vectors | OSKM |
Table 3 Differentiation and application of urine-derived stem cells and urine-derived pluripotent stem cells
| Cells | Differentiation | Factors | Diseases/animal model | Ref. |
| USCs | NPCs | hEGF, bFGF | [28] | |
| Neural lineage cells (astrocytes) | Transplantation | CCI model (rat) | [28] | |
| Neurons | Laminin, PDGF-BB | |||
| VPA, CHIR99021, repsox, forskolin, SP600625, GO6983, Y27632 | ||||
| NSCs | Cocktail (P, F, V, N) and srRNA (with OSKG) | |||
| Osteoblasts | Silver nanoparticles | Bone defect model | ||
| Y-27632 | ||||
| Calcium silicate ionic, BMP2 | ||||
| BMP2, FAK | ||||
| BCP-CS | ||||
| Surface mineralized BCP | [19] | |||
| BMP2-CSM/Col I hydrogel | ||||
| Chondrocytes | Hyaluronic acid with USCs | |||
| Y-27632 | ||||
| ACM scaffolds | ||||
| Muscle cells | VEGF, IGF-1, FGF-1, PDGF-BB, HGF, NGF | |||
| HD myogenic differentiation medium | [103] | |||
| Lentiviral with MYOD | ||||
| hp-HA (IGF-1, HGF, PDGF-BB) | ||||
| Hepatocytes | Co-culture with HPCs | [5] | ||
| UiPSCs | Cardiac myocytes | Activin A, bFGF, BMP4, DKK1, VEGF | [56] | |
| Cardiomyocyte differentiation kit (Gibco, catA2921201) | ||||
| CHIR99021, BIO, KY02111, IWP2 | ||||
| GIWI2 | ||||
| HIR99021, IWP2 | MI (rat) | |||
| KPCs | AKI | [69] | ||
| Kidney organoids | Y-27632, APEL-2, CHIR99021, hFGF9, heparin | |||
| Neurons, astrocytes | Transplantation | SCI model (rat) | ||
| NPCs | N2B27, dorsomorphin, SB4315242 | |||
| HPCs | Flavonoid | |||
| Muscle cells | CHIR99021 | [52] | ||
| Neurons, astrocytes, VECs | Simulate the brain microenvironment of diabetes mellitus | |||
| RCs, CCs | RDM | |||
| LB | BMP, BMP4, BMP7, bFGF, WNT3A | |||
| AECs II | ||||
| Hepatocytes |
- Citation: Yang HS, Zheng YX, Bai X, He XY, Wang TH. Application prospects of urine-derived stem cells in neurological and musculoskeletal diseases. World J Orthop 2024; 15(10): 918-931
- URL: https://www.wjgnet.com/2218-5836/full/v15/i10/918.htm
- DOI: https://dx.doi.org/10.5312/wjo.v15.i10.918
